Authors
Latest:
Dr. Stilgenbauer on Activity With Venetoclax in Patients With CLLStephen Stilgenbauer, MD, associate professor, Department of Haematology, Oncology, Rheumatology and Infectious Diseases, University of Ulm, Germany, discusses the clinical activity seen with venetoclax in patients with chronic lymphocytic leukemia, according to results of the open-label, single-arm, multicenter M13-982 study.
Latest:
Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder CancerStephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.
Latest:
Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before TransplantStevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.
Latest:
Everolimus Shows Robust Activity in Lung/GI NETsEverolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.
Latest:
Dr. Fischkoff on Vision for TIL Therapy in MelanomaSteven A. Fischkoff, MD, chief medical officer of Lion Biotechnologies, Inc, discusses his vision for tumor-infiltrating lymphocyte therapy for patients with melanoma.
Latest:
Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell TherapySteven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.
Latest:
Therapy of Non-Small Cell Lung Cancer: Past, Present, and FutureNew and relevant studies are examining the role of histology, biomarkers, and growth factor receptor inhibitors in the treatment of NSCLC.
Latest:
Dr. Toms on Targeting MEK as a Treatment Strategy for CNS MetastasisSteven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.
Latest:
Steven Buechler Discusses EarlyR Gene Signature in the BIG 1-98 Trial for Breast CancerSteven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group (BIG) 1-98 study. This randomized, double-blind, phase III trial compared letrozole with tamoxifen as an adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Latest:
Dr. Campbell Discusses the Goals of the New RCC GuidelinesSteven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the goals of the newly updated guidelines in renal cell carcinoma.
Latest:
Dr. Coutre Discusses Combination Strategies in ALLSteven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses combination strategies for the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Clinician's View: Making Survival a Blessing, Not a BurdenMore and more deadly diseases are slowly being transformed into chronic conditions. This is especially true of cancer.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Shooting for the Moon…and BeyondThis is an exciting time, as reports of major news impacting oncology research are emerging, it seems, on a daily basis.
Latest:
Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized SarcomaAs clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr. Lin on Chemoradiation in Elderly Patients with Esophageal CancerSteven H. Lin, MD, PhD, associate professor at The University of Texas MD Anderson Center, discusses study of chemoradiation in elderly patients with esophageal cancer.
Latest:
Dr. Horwitz on Ongoing Trials in T-Cell LymphomaSteven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.
Latest:
Dr. Park on Alisertib in Myc-Overexpressing Lymphoma CellsSteven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.
Latest:
Dr. Sherman Defines RAI Resistance in Thyroid CancerSteven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.
Latest:
Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNSSteven J. DiBiase, MD, chair and chief of service for the Julia and Ned Arnold Center for Radiation Oncology, NewYork-Presbyterian Queens, vice chairman and assistant interim professor of radiation oncology, Weill Cornell Medicine, discusses data with 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation in cancers involving the central nervous system (CNS).
Latest:
Payers Manipulate Definition of NecessityWhen it comes to health coverage, most Americans face an unnerving reality—they have no idea what is covered under their health insurance policy until they are affected by illness or disease.
Latest:
How Genetic Testing Impacts Breast Cancer Treatment DecisionsAs genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions.
Latest:
Dr. Katz on Precision Medicine in Breast CancerSteven Katz, MD, professor, Internal Medicine, University of Michigan Health System, discusses the incorporation of precision medicine into the treatment paradigm of breast cancer.
